216 related articles for article (PubMed ID: 24073198)
1. Oncolytic reovirus in canine mast cell tumor.
Hwang CC; Umeki S; Kubo M; Hayashi T; Shimoda H; Mochizuki M; Maeda K; Baba K; Hiraoka H; Coffey M; Okuda M; Mizuno T
PLoS One; 2013; 8(9):e73555. PubMed ID: 24073198
[TBL] [Abstract][Full Text] [Related]
2. The effects of oncolytic reovirus in canine lymphoma cell lines.
Hwang CC; Umeki S; Igase M; Coffey M; Noguchi S; Okuda M; Mizuno T
Vet Comp Oncol; 2016 Aug; 14 Suppl 1():61-73. PubMed ID: 25319493
[TBL] [Abstract][Full Text] [Related]
3. The oncolytic effects of reovirus in canine solid tumor cell lines.
Igase M; Hwang CC; Coffey M; Okuda M; Noguchi S; Mizuno T
J Vet Med Sci; 2015 May; 77(5):541-8. PubMed ID: 25648933
[TBL] [Abstract][Full Text] [Related]
4. Reovirus changes the expression of anti-apoptotic and proapoptotic proteins with the c-kit downregulation in canine mast cell tumor cell lines.
Hwang CC; Igase M; Okuda M; Coffey M; Noguchi S; Mizuno T
Biochem Biophys Res Commun; 2019 Sep; 517(2):233-237. PubMed ID: 31345575
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic reovirus synergizes with chemotherapeutic agents to promote cell death in canine mammary gland tumor.
Igase M; Hwang CC; Kambayashi S; Kubo M; Coffey M; Miyama TS; Baba K; Okuda M; Noguchi S; Mizuno T
Can J Vet Res; 2016 Jan; 80(1):21-31. PubMed ID: 26733729
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumour activity of oncolytic reovirus against canine histiocytic sarcoma cells.
Igase M; Shousu K; Fujiki N; Sakurai M; Bonkobara M; Hwang CC; Coffey M; Noguchi S; Nemoto Y; Mizuno T
Vet Comp Oncol; 2019 Jun; 17(2):184-193. PubMed ID: 30761736
[TBL] [Abstract][Full Text] [Related]
7. Reovirus as a viable therapeutic option for the treatment of multiple myeloma.
Thirukkumaran CM; Shi ZQ; Luider J; Kopciuk K; Gao H; Bahlis N; Neri P; Pho M; Stewart D; Mansoor A; Morris DG
Clin Cancer Res; 2012 Sep; 18(18):4962-72. PubMed ID: 22761466
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic reovirus therapy: Pilot study in dogs with spontaneously occurring tumours.
Hwang CC; Igase M; Sakurai M; Haraguchi T; Tani K; Itamoto K; Shimokawa T; Nakaichi M; Nemoto Y; Noguchi S; Coffey M; Okuda M; Mizuno T
Vet Comp Oncol; 2018 Jun; 16(2):229-238. PubMed ID: 29076241
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.
Heinemann L; Simpson GR; Boxall A; Kottke T; Relph KL; Vile R; Melcher A; Prestwich R; Harrington KJ; Morgan R; Pandha HS
BMC Cancer; 2011 Jun; 11():221. PubMed ID: 21645351
[TBL] [Abstract][Full Text] [Related]
10. Morbidity in immunosuppressed (SCID/NOD) mice treated with reovirus (dearing 3) as an anti-cancer biotherapeutic.
Loken SD; Norman K; Hirasawa K; Nodwell M; Lester WM; Demetrick DJ
Cancer Biol Ther; 2004 Aug; 3(8):734-8. PubMed ID: 15197356
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic Viral Therapy Using Reovirus.
Thirukkumaran C; Morris DG
Methods Mol Biol; 2015; 1317():187-223. PubMed ID: 26072409
[TBL] [Abstract][Full Text] [Related]
12. Virotherapy of canine tumors with oncolytic vaccinia virus GLV-1h109 expressing an anti-VEGF single-chain antibody.
Patil SS; Gentschev I; Adelfinger M; Donat U; Hess M; Weibel S; Nolte I; Frentzen A; Szalay AA
PLoS One; 2012; 7(10):e47472. PubMed ID: 23091626
[TBL] [Abstract][Full Text] [Related]
13. Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma.
Pandha HS; Heinemann L; Simpson GR; Melcher A; Prestwich R; Errington F; Coffey M; Harrington KJ; Morgan R
Clin Cancer Res; 2009 Oct; 15(19):6158-66. PubMed ID: 19773377
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic reovirus induces intracellular redistribution of Ras to promote apoptosis and progeny virus release.
Garant KA; Shmulevitz M; Pan L; Daigle RM; Ahn DG; Gujar SA; Lee PW
Oncogene; 2016 Feb; 35(6):771-82. PubMed ID: 25961930
[TBL] [Abstract][Full Text] [Related]
15. Modulation of Reoviral Cytolysis (I): Combination Therapeutics.
Mori Y; Nishikawa SG; Fratiloiu AR; Tsutsui M; Kataoka H; Joh T; Johnston RN
Viruses; 2023 Jun; 15(7):. PubMed ID: 37515160
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic reovirus effectively targets breast cancer stem cells.
Marcato P; Dean CA; Giacomantonio CA; Lee PW
Mol Ther; 2009 Jun; 17(6):972-9. PubMed ID: 19293772
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic reovirus combined with trastuzumab enhances antitumor efficacy through TRAIL signaling in human HER2-positive gastric cancer cells.
Hamano S; Mori Y; Aoyama M; Kataoka H; Tanaka M; Ebi M; Kubota E; Mizoshita T; Tanida S; Johnston RN; Asai K; Joh T
Cancer Lett; 2015 Jan; 356(2 Pt B):846-54. PubMed ID: 25444894
[TBL] [Abstract][Full Text] [Related]
18. Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic.
Thirukkumaran CM; Nodwell MJ; Hirasawa K; Shi ZQ; Diaz R; Luider J; Johnston RN; Forsyth PA; Magliocco AM; Lee P; Nishikawa S; Donnelly B; Coffey M; Trpkov K; Fonseca K; Spurrell J; Morris DG
Cancer Res; 2010 Mar; 70(6):2435-44. PubMed ID: 20215509
[TBL] [Abstract][Full Text] [Related]
19. Exploring host factors that impact reovirus replication, dissemination, and reovirus-induced cell death in cancer versus normal cells in culture.
Shmulevitz M; Lee PW
Methods Mol Biol; 2012; 797():163-76. PubMed ID: 21948476
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma.
Errington F; White CL; Twigger KR; Rose A; Scott K; Steele L; Ilett LJ; Prestwich R; Pandha HS; Coffey M; Selby P; Vile R; Harrington KJ; Melcher AA
Gene Ther; 2008 Sep; 15(18):1257-70. PubMed ID: 18401435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
